



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/851,670	05/08/2001	Christoph Reinhard	PP-01699.002/200130.520	3261

7590

05/08/2002

Chiron Corporation
Intellectual Property R338
P.O. Box 8097
Emeryville, CA 94662-8097

EXAMINER

SCHMIDT, MARY M

ART UNIT

PAPER NUMBER

1635

DATE MAILED: 05/08/2002

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

09/851,670

Applicant(s)

REINHARD ET AL.

Examiner

Mary Schmidt

Art Unit

1635

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☐ Responsive to communication(s) filed on _____.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-18 is/are pending in the application.
- 4a) Of the above claim(s) 6 and 7 is/are withdrawn from consideration.
- 5) ☒ Claim(s) 17 and 18 is/are allowed.
- 6) ☒ Claim(s) 1-4 and 8-16 is/are rejected.
- 7) ☒ Claim(s) 5 is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on _____ is: a) ☐ approved b) ☐ disapproved by the Examiner.
- If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

- 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
- a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☒ Information Disclosure Statement(s) (PTO-1449) Paper No(s) 3.
- 4) ☐ Interview Summary (PTO-413) Paper No(s). _____.
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☐ Other:

Art Unit: 1635

DETAILED ACTION

1. Applicant's election of Group I, claims 1, 2-5, and 8-18, in Paper No. 9, filed 2/12/02, is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.03(a)).

2. Claims 6 and 7 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim.

Election was made **without** traverse in Paper No. 9, filed 2/12/02. (Please note that cancellation of claims 6 and 7 as well as the non-elected embodiments of claim 1 (ribozyme, protein, polypeptide, antibody and small molecule) will be required in a subsequent final Official Action.)

Claim Objections

3. Claims 2, 10 and 14 are objected to under 37 CFR 1.75(c), as being of improper dependent form for failing to further limit the subject matter of a previous claim. Applicant is required to cancel the claim(s), or amend the claim(s) to place the claim(s) in proper dependent form, or rewrite the claim(s) in independent form. Claim 1 is drawn to an isolated Akt3 inhibitor consisting of an antisense oligonucleotide upon election of Group I in the previous restriction requirement. Claim 2 further specifies that the Akt3 inhibitor is an antisense and does not further limit the breadth of claim 1. Similarly claims 10 and 14 depend from claims which further

Art Unit: 1635

specify the claimed inhibitor is an antisense, and in view of the response to the restriction requirement, said claims are essential duplicates of the parent claims 8 and 13, respectively.

Claim Rejections - 35 USC § 112

4. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

5. Claims 1-5 and 8-15 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

The claims are drawn to broadly to antisense inhibitors of any Akt3 from any species. The prior art taught that the gene sequence of rat and human Akt3 were known (Konishi et al. (Taugh isolation of the rat Akt3 gene sequence); Nakatani et al., Brodbeck et al., and Masure et al. (All taught isolation of the human Akt3 sequence)).

Neither the specification nor the art provided guidance for design of antisense to Akt3 genes from other species of organisms.

Art Unit: 1635

MPEP 2163 teaches the following conditions for the analysis of the claimed invention at the time the invention was made in view of the teachings of the specification and level of skill in the art at the time the invention was made:

The claimed invention as a whole may not be adequately described where an invention is described solely in terms of a method of its making coupled with its function and there is no described or art-recognized correlation or relationship between the structure of the invention and its function. A biomolecule sequence described only by a functional characteristic, without any known or disclosed correlation between that function and the structure of the sequence, normally is not a sufficient identifying characteristic for written description purposes, even when accompanied by a method of obtaining the claimed sequence....A lack of written description issue also arises if the knowledge and level of skill in the art would not permit one skilled in the art to immediately envisage the product claimed from the disclosed process....Generally, there is an inverse correlation between the level of skill and knowledge in the art and the specificity of disclosure necessary to satisfy the written description requirement....The written description requirement for a claimed genus may be satisfied through sufficient description of a representative number of species by actual reduction to practice..., reduction to drawings..., or by disclosure of relevant, identifying characteristics, i.e., structure or other physical and/or chemical properties, by functional characteristics coupled with a known or disclosed correlation between function and structure, or by a combination of such identifying characteristics, sufficient to show the applicant was in possession of the claimed genus.

Neither the specification nor the art taught the sequence structure of Akt3 genes other than human or rat. Neither the specification nor the art provided guidance with which to immediately envisage the sequence of the Akt3 gene from any other organism. Since a representative number of species of Akt3 genes from any such other organism were not known at the time the invention was made, Applicant was not in possession of a representative number of any antisense as claimed to any Akt3 gene from any organism. Therefore, while Applicant was

Art Unit: 1635

in possession of antisense to human Akt3 at the time the invention was made, Applicant was not in possession of the breadth of antisense compositions claimed to Akt3 from any other species.

6. Claims 13-15 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for antisense to Akt3 use in cells in culture (*in vitro*), does not reasonably provide enablement for any antisense nucleic acid sequence to Akt3 for use in whole organisms as broadly claimed. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention commensurate in scope with these claims.

Claims 13 and 14 are drawn to methods of decreasing the expression of Akt3 in a mammalian cell, comprising administering an Akt3 inhibitor (and in view of the election of antisense, an antisense inhibitor). Claim 15 is drawn to a method of treating neoplastic disease comprising administering to a mammalian cell an Akt3 inhibitor (ie. an antisense inhibitor).

There is a high level of unpredictability known in the antisense art for therapeutic, *in vivo* (whole organism) applications. The factors considered barriers to successful delivery of antisense delivery to the organism are: (1) penetration of the plasma membrane of the target cells to reach the target site in the cytoplasm or nucleus, (2) withstanding enzymatic degradation, and (3) the ability to find and bind the target site and simultaneously avoid non-specific binding (see Branch). Note also Ma et al. who teach (on page 167) that "to gain therapeutic advantage using antisense-based technology, ODNs must have certain characteristics. They must be

Art Unit: 1635

resistant to degradation, internalize efficiently, hybridize in a sequence specific manner with the target nucleic acid, display adequate bioavailability with a favorable pharmacokinetic profile and be nontoxic.” Despite the synthesis of more resilient, nuclease resistant, oligonucleotide backbones and isolated successes with antisense therapy *in vivo*, the majority of designed antisense molecules still face the challenge of successful entry and localization to the intended target and further such that antisense and other effects can routinely be obtained. Flanagan teaches, “oligonucleotides (*in vivo*) are not distributed and internalized equally among organs and tissues.... Unfortunately, therapeutically important sites such as solid tumors contain very little oligonucleotide following intravenous injections in animals (page 51, column 2).” Ma et al. supports the difficulties of *in vivo* use of ODNs on pages 160-172. Jen et al. further taught that “given the state of the art, it is perhaps not surprising that effective and efficient clinical translation of the antisense strategy has proven elusive. While a number of phase I/II trials employing ONs have been reported..., virtually all have been characterized by a lack of toxicity but only modest clinical effects.” (Page 315, col. 2) Green et al. summarizes that “the future of nucleic acid therapeutics using antisense ODNs ultimately depends on overcoming the problems of potency, stability, and toxicity; the complexity of these tasks should now be apparent. Improvements in delivery systems and chemical modifications may lead to safer and more efficacious antisense compounds with improved pharmacokinetics and reduced toxicities.” (P. 103, col. B) Note also some of the major outstanding questions that remain in the art taught by Agrawal et al. On page 79, col. 2.

Art Unit: 1635

In vitro, antisense specificity to its target may be manipulated by “raising the temperature or changing the ionic strength, manipulations that are commonly used to reduce background binding in nucleic acid hybridization experiments.” (Branch, p. 48) Note also Ma et al. who teach that “*in vitro* subcellular distribution is dependent on the type of ODN modification, cellular system and experimental conditions. ODNs, once internalized, are distributed to a variety of subcellular compartments.” (Page 168) Discovery of antisense molecules with “enhanced specificity” *in vivo* requires further experimentation for which no guidance is taught in the specification. Note Branch who teaches the state of the art for designing an antisense which inhibits a target *in vivo*: it “is very difficult to predict what portions of an RNA molecule will be accessible *in vivo*, effective antisense molecules must be found empirically by screening a large number of candidates for their ability to act inside cells (Branch, p.49).” Note Jen et al. who teach that “although mRNA targeting is impeccable in theory, many additional considerations must be taken into account in applying these strategies in living cells including mRNA site selection, drug delivery and intracellular localization of the antisense agent.” (Abstract) Bennett et al. further taught that “although the antisense paradigm holds great promise, the field is still in its early stages, and there are a number of key questions that need to be answered and technical hurdles that must be overcome....The key issues concerning this class of chemicals center on whether these compounds have acceptable properties as drugs. These include pharmacokinetic, pharmacological and toxicological properties.” (Page 13) As argued above, these issues remain unpredictable in the art for antisense oligonucleotide administration *in vivo*.

Art Unit: 1635

One of skill in the art would not accept on its face the successful delivery of the disclosed antisense molecules *in vivo* and further, treatment effects, in view of the lack of guidance in the specification and the unpredictability in the art. Neither the specification nor technology today teach general guidelines for successful delivery or treatment effects of antisense molecules in whole organisms. Specifically the specification does not teach (1) stability of the antisense molecule *in vivo*, (2) effective delivery to the whole organism and specificity to the target tissues, (3) dosage and toxicity, nor (4) entry of molecule into cell and effective action therein marked by visualization of the desired treatment effects. These key factors are those found to be highly unpredictable in the art as discussed *supra*. The lack of guidance in the specification as filed for these factors would therefore require "trial and error" experimentation beyond which is taught by the specification as filed. Therefore, it would require undue experimentation to practice the invention as claimed.

Claim Rejections - 35 USC § 102

7. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless --

(e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371© of this title before the invention thereof by the applicant for patent.

Art Unit: 1635

8. Claims 1-4, 8-11, 13-14 and 16 are rejected under 35 U.S.C. 102(b) as being anticipated by Monia et al., U.S. Patent No. 6,187,586.

The instant rejection over instant claims 13 and 14 is made for the enabled scope of those methods for use in cells in cell culture (*in vitro*).

Monia et al. taught antisense targeting human Akt3 inhibitors having at least 10 consecutive nucleic acids of SEQ ID NO:1, including those from 8 to 35 nucleic acids (instant claims 1-4 and 16) throughout U.S. Patent 6,197, 596, but especially from col. 38 to col. 44). They further taught compositions comprising pharmaceutically acceptable carriers from col. 10 to col. 23 (instant claims 8, 10-11). They specifically taught use of compositions comprising two or more Akt3 inhibitors in col. 23 (instant claim 9). They taught methods of decreasing the expression of Akt3 in mammalian cells via administration of antisense to cells in culture (instant claims 13 and 14) in col. 33 and 34.

Monia et al. thus anticipated the claimed invention.

9. Claims 17 and 18 are allowable. However, the claims would be more clearly written if amended to add a limitation to the claims specifying the function as wherein the antisense oligonucleotide inhibits the expression of human Akt3.

10. Claims 5, 12, 17 and 18 are free of the prior art since the prior art does not teach the specific sequences in SEQ ID NOS: 2-6 and 12-19, specific antisense nucleic acids to human

Art Unit: 1635

Akt3 claimed in claim 5, nor methods of using said sequences in cells in cell culture (the enabled scope of claim 12), nor vectors encoding said specific sequences as claimed in claims 17 and 18. The closest prior art, Monia et al., U.S. Patent 6,197, 596, did not teach the antisense comprising the sequences of SEQ ID NOS: 2-6 and 12-19 instantly claimed.

11. Any inquiry concerning this communication or earlier communications from the examiner should be directed to *Mary M. Schmidt*, whose telephone number is (703) 308-4471.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, *John LeGuyader*, may be reached at (703) 308-0447.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group Analyst, *Katrina Turner*, whose telephone number is (703) 305-3413.

M. M. Schmidt
May 6, 2002



JOHN L. LeGUYADER
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600